Circulating 25-Hydroxyvitamin D and Prostate Cancer Survival
Mondul AM, Weinstein SJ, Moy KA, Männistö S, Albanes D
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 36 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institutes of Health
- Gobierno
- U.S. Public Health Service
- Gobierno
- National Cancer Institute
- Gobierno
- NCI NIH HHS
- Gobierno
- CCR NIH HHS
- Gobierno
- Intramural NIH HHS
- Subvenciones
- U.S. Public Health Service (HHSN261200800001E); U.S. Public Health Service (N01-RC-37004); U.S. Public Health Service (HHSN261201000006C); National Cancer Institute (HHSN261200800001E)); U.S. Public Health Service (N01-CN-45165); National Cancer Institute (HHSN261201000006C); National Cancer Institute (HHSN261201500005C); U.S. Public Health Service (HHSN261201500005C); National Institutes of Health (HHSN261200800001C); National Cancer Institute (N01 CN045165); U.S. Public Health Service (N01-RC- 45035); National Institutes of Health (N01 RC037004); National Institutes of Health (Z01 CP010195)
Según 6 financiadores declarados.
Publicación
- Publicado
- 2016-01-25 · Cancer Epidemiol Biomarkers Prev · vol. 25 · número 4 · págs. 665–669
- Editorial
- American Association for Cancer Research
- Citado
- 58 citas · más que el 97% de estudios similares · 6.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 25 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Vitamin D Research Studies · Bone health and treatments · Thyroid Disorders and Treatments
- Palabras clave
- Prostate cancer, Medicine, Hazard ratio, Cancer, Vitamin D and neurology, Internal medicine, Proportional hazards model, Prostate, Confidence interval, Oncology, Population, Cohort, Malignancy, Cohort study, Gynecology
- MeSH
- humans, prostatic neoplasms, vitamin d, survival analysis, double-blind method, aged, middle aged, male
5 autores
- Alison M. Mondul🇺🇸 · autor de correspondenciaUniversity of Michigan; Department of Health and Human Services
- Stephanie J. Weinstein🇺🇸Department of Health and Human Services
- Kristin A. Moy🇺🇸Department of Health and Human Services
- Satu Männistö🇫🇮Finnish Institute for Health and Welfare
- Demetrius Albanes🇺🇸Department of Health and Human Services
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Recent epidemiologic evidence suggests that higher circulating vitamin D does not protect against prostate cancer and, in fact, may increase the risk of developing this malignancy. However, few studies have examined the most clinically relevant outcome, prostate cancer mortality.
Methods
We examined prediagnostic serum 25-hydroxy-vitamin D (25(OH)D) and prostate cancer survival in a cohort of 1,000 cases in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. During 23 years of follow-up, 363 men died from their disease. Cox proportional hazards models were used to estimate the hazard ratio (HR) and 95% confidence interval (CI) of death from prostate cancer by season-specific quintile of 25(OH)D. Multivariable models were adjusted for age, physical activity, cigarettes per day, and family history of prostate cancer.
Results
Men with higher serum 25(OH)D were less likely to die from their prostate cancer (Q5 vs. Q1 HR, 0.72; 95% CI, 0.52-0.99; Ptrend = 0.006). This finding was independent of stage or grade at diagnosis and appeared restricted to men who survived longer (survived <3.3 years: Q5 vs. Q1 HR, 0.95; 95% CI, 0.61-1.50; Ptrend, 0.53; survived ≥3.3 years: Q5 vs. Q1 HR, 0.53; 95% CI, 0.34-0.85; Ptrend, 0.0002).
Conclusions
In this population of men diagnosed with prostate cancer, higher serum 25(OH)D years prior to diagnosis was associated with longer prostate cancer survival.
Impact
In light of inconsistent evidence regarding the role of vitamin D in the development of prostate cancer, the present findings regarding the most clinically relevant prostate cancer outcome, disease-specific mortality, could have important public health implications. Cancer Epidemiol Biomarkers Prev; 25(4); 665-9. ©2016 AACR.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.